Price
No data yet.
Social Signal Score
Analyst Ratings
36 analystsRevenue
$1.72B+104057.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Karen Massey
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,863
- Beta
- -0.02
- Country
- NL
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 21.94
Financials
Revenue
$1.72B+104057.8%Net Income
$506.00MEBITDA
$539.00MFree Cash Flow
—EPS (diluted)
$7.80Shares Outstanding (diluted)
64.89M+313.2%Operating Expenses
$1.10BCash & Debt
—Return of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.15B | $1.29B | $21.14 |
| 2024 | $2.19B | $833.04M | $13.92 |
| 2023 | $1.23B | $-295.05M | $-5.16 |
| 2022 | $410.75M | $-709.59M | $-13.05 |
| 2021 | $1.08B | $-408.26M | $-7.99 |
| 2020 | $41.24M | $-608.46M | $-13.40 |
| 2019 | $78.46M | $-181.21M | $-4.69 |
| 2018 | $24.57M | $-76.23M | $-2.12 |
| 2017 | $43.69M | $-33.68M | $-1.37 |
| 2016 | $15.47M | $-22.48M | $-1.19 |
| 2015 | $7.49M | $-16.74M | $-1.06 |
| 2014 | $4.57M | $-12.54M | $-0.80 |
| 2013 | $3.70M | $-8.47M | $-0.54 |
| 2012 | $2.18M | $-12.83M | $-0.82 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $30.97
- Implied price
- $1,239
- Return from $941.25
- 5.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $615.94 — -34.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 28 | 34 | 40 | 46 | 52 |
|---|---|---|---|---|---|
| -2.0% | -10.7% | -7.2% | -4.1% | -1.4% | 1.0% |
| 3.0% | -6.2% | -2.5% | 0.8% | 3.6% | 6.2% |
| 8.0% | -1.6% | 2.3% | 5.6% | 8.6% | 11.3% |
| 13.0% | 2.9% | 7.0% | 10.5% | 13.7% | 16.5% |
| 18.0% | 7.5% | 11.7% | 15.4% | 18.7% | 21.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
60+100.00%Social Signal Score
Mentions (27)
- Newsfool.com·13d ago·Neutral
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
argenx to Present at Upcoming Investor Conferences November 3, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that members of the management team will participate in the following investor conferences in November: Guggenheim 3rd Annual Healthcare Innovation Conference. Fireside chat on Tuesday, November 10 at 2:00 p.m.
View source ↗ - Newsseekingalpha.com·31d ago·Positive
argenx SE (ARGX) Q3 2026 Earnings Call Transcript argenx SE ( ARGX ) Q3 2026 Earnings Call October 22, 2026 8:30 AM EDT Company Participants Beth DelGiacco Karen Massey - CEO & Executive Director Karl Gubitz - Chief Financial Officer Sandrine Piret-Gerard - Chief Commercialization Officer Luc Truyen - Chief Medical Officer Conference Call Participants Daniel Giraldo Perez - BofA Securities, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Victor Floch - BNP Pariba…
View source ↗ - Newsmarketbeat.com·31d ago·Positive
What argenex (ARGX) Said on Its Q3 Earnings Call argenex NASDAQ: ARGX reported third-quarter 2026 product net sales of $1.7 billion, up 54% from a year earlier and 13% sequentially, as patient growth in generalized myasthenia gravis, or MG, and chronic inflammatory demyelinating polyneuropathy, or CIDP, continued to support demand for VYVGART.
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 October 15, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will host a conference call and audio webcast on Thursday, October 22, 2026 at 2:30 PM CET (8:30 AM ET) to discuss its third quarter 2026 financial results and provide a business update.
View source ↗ - Newsbusinesswire.com·41d ago·Negative
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $ARGX--ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law.
View source ↗ - Newszacks.com·44d ago·Neutral
argenx Meets Primary Endpoint in Phase II Celiac Disease Study ARGX's FB102 achieves its primary endpoint in a phase II celiac disease study, paving the way for late-stage development despite a nearly 12% stock drop.
View source ↗ - Newszacks.com·44d ago·Neutral
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
View source ↗ - Newsseekingalpha.com·44d ago·Neutral
argenx: The Sjögren's Selloff Looks Overdone argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. VYVGART franchise remains robust, driving strong cash generation and funding pipeline advancements, despite setbacks in expanding indications. At ~8x annualized sales, ARGX trades at a discount to peers like Vertex, supporting a reiterated 'Buy' rating based on growth prospects.
View source ↗ - Newsprnewswire.com·45d ago·Neutral
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX) ARGX share price fell sharply after a futility finding resulted in the discontinuation of a pending Phase 3 trial. SueWallSt notifies investors of a pending investigation.
View source ↗ - Newsproactiveinvestors.com·45d ago·Negative
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted Shares in argenx SE (NASDAQ:ARGX) fell nearly 15% in New York on Thursday after it discontinued a late-stage trial of its drug Vyvgart in Sjögren's disease. Sjögren's disease is a chronic autoimmune condition characterized by immune-mediated destruction of the glands that produce tears and saliva, causing symptoms including dry eyes and mouth.
View source ↗ - Newsbenzinga.com·45d ago·Neutral
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session U.S. stock futures were lower this morning, with the Dow futures falling around 450 points on Thursday.
View source ↗ - Newswsj.com·45d ago·Negative
Argenx Shares Plunge After Autoimmune-Disease Trial Halt The stock was down 18%, wiping out year-to-date gains after the biotech stopped a late-stage clinical trial of its Vyvgart drug due to lack of efficacy.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…with celiac disease argenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease. These results represent the first clinical readout of FB102 following argenx's acquisition of Forte Biosciences in August 2026.
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
…rovides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The decision is based on the recommendation from an Independent Data Monitoring Committee (I…
View source ↗ - Newsfool.com·48d ago·Positive
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? This biotech stock could soar 30% or more over the next 12 months if some analysts are right.
View source ↗ - Newsglobenewswire.com·54d ago·Positive
…lts in MMN support its potential as a pathway-selective complement therapy September 29, 2026, 8:00 AM EST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, will present new data from across its portfolio and pipeline at the 2026 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and the Myasthenia Gravis Foundation of America (MGFA) Scientific Session in Orlando, Florida, from September 29 – October 2…
View source ↗ - Newsfool.com·57d ago·Positive
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months Argenx's Vyvgart franchise enjoys strong sales momentum. The company has multiple registrational data read-outs on the way.
View source ↗ - Newsfool.com·63d ago·Neutral
2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right. Wells Fargo and UBS have 12-month price targets for Argenx that are more than 40% above the current share price. Argenx's momentum and clinical successes appear to justify these lofty expectations.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsfool.com·81d ago·Negative
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
argenx to Present at Upcoming Investor Conferences September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
View source ↗ - Newsfool.com·88d ago·Negative
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
View source ↗ - Newszacks.com·96d ago·Negative
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
View source ↗ - Newsseekingalpha.com·96d ago·Positive
argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis Transcript
View source ↗ - Newsreuters.com·97d ago·Negative
Argenx says efgartigimod met main goal in myositis trial Belgian-Dutch immunology company argenx ARGX.BR said its drug efgartigimod met the primary endpoint in a late-stage study treating adults with autoimmune myositis, showing significant improvement in disease activity.
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $7.39 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$7.80 vs $7.44beat
- Thu, May 7$5.90 vs $5.16beat
- Thu, Oct 30$5.18 vs $4.37beat
- Thu, May 8$2.58 vs $2.32beat
- Thu, Oct 31$1.39 vs $0.10beat
- Thu, May 9$-1.04 vs $-0.71miss
Estimates and results for ARGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (26d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (27d later)Buy$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (14d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (113d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
